Inhibition of growth factor production and angiogenesis in human cancer cells by ZD1839 (Iressa), a selective epidermal growth factor receptor tyrosine kinase inhibitor.

No abstract is available for this paper.

• Publication year

  2001

• Venue

  Clinical Cancer Research

• Publication date

  2001-05-01

• Fields of study

  Biology, Medicine

• Identifiers
  PMID 11350918
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Tumor angiogenesis

  2020cited by this paper
• The role of vascular endothelial growth factor in pathological angiogenesis

  2004cited by this paper
• Type I Receptor Tyrosine Kinases as Targets for Therapy in Breast Cancer

  2004cited by this paper
• Antitumor effect and potentiation of cytotoxic drugs activity in human cancer cells by ZD-1839 (Iressa), an epidermal growth factor receptor-selective tyrosine kinase inhibitor.

  2000influential reference
• Tyrosine kinase inhibitors targeted to the epidermal growth factor receptor subfamily: role as anticancer agents.

  2000cited by this paper
• Antiangiogenic and antitumor activity of anti-epidermal growth factor receptor C225 monoclonal antibody in combination with vascular endothelial growth factor antisense oligonucleotide in human GEO colon cancer cells.

  2000cited by this paper
• Anti-epidermal growth factor receptor antibody C225 inhibits angiogenesis in human transitional cell carcinoma growing orthotopically in nude mice.

  2000cited by this paper
• Blockade of the epidermal growth factor receptor signaling by a novel tyrosine kinase inhibitor leads to apoptosis of endothelial cells and therapy of human pancreatic carcinoma.

  2000cited by this paper
• Epidermal growth factor receptor blockade with C225 plus gemcitabine results in regression of human pancreatic carcinoma growing orthotopically in nude mice by antiangiogenic mechanisms.

  2000cited by this paper
• Anticancer drug targets: growth factors and growth factor signaling.

  2000cited by this paper
• Anti-epidermal growth factor receptor antibody C225 inhibits angiogenesis in human transitional cell carcinoma growing orthotopically in nude mice.

  1999cited by this paper
• The epidermal growth factor receptor and its inhibition in cancer therapy.

  1999influential reference
• Evaluation of epidermal growth factor-related growth factors and receptors and of neoangiogenesis in completely resected stage I-IIIA non-small-cell lung cancer: amphiregulin and microvessel count are independent prognostic indicators of survival.

  1998influential reference
• The Molecular Basis of Cancer

  1998cited by this paper
• Therapeutic application of anti‐growth factor receptor antibodies

  1998cited by this paper
• Neutralizing antibodies against epidermal growth factor and ErbB-2/neu receptor tyrosine kinases down-regulate vascular endothelial growth factor production by tumor cells in vitro and in vivo: angiogenic implications for signal transduction therapy of solid tumors.

  1997cited by this paper
• Transforming growth factor‐α‐induced transcriptional activation of the vascular permeability factor (VPF/VEGF) gene requires AP‐2‐dependent DNA binding and transactivation

  1997cited by this paper
• Clinical applications of research on angiogenesis

  1996cited by this paper
• Regulation of Angiogenesis

  1996cited by this paper
• The microtubule-affecting drug paclitaxel has antiangiogenic activity.

  1996cited by this paper
• Growth inhibition of human colon carcinoma cells by combinations of anti-epidermal growth factor-related growth factor antisense oligonucleotides.

  1996cited by this paper
• Antitumor activity of combined blockade of epidermal growth factor receptor and protein kinase A.

  1996influential reference
• Seminars in Medicine of the Beth Israel Hospital, Boston. Clinical applications of research on angiogenesis.

  1995cited by this paper
• Epidermal growth factor-related peptides and their receptors in human malignancies.

  1995cited by this paper
• Clinical importance of the determination of tumor angiogenesis in breast carcinoma: much more than a new prognostic tool.

  1995cited by this paper
• Epidermal growth factor stimulates vascular endothelial growth factor production by human malignant glioma cells: a model of glioblastoma multiforme pathophysiology.

  1993cited by this paper
• Autocrine Secretion—10 Years Later

  1992cited by this paper
• Relation of neovascularisation to metastasis of non-small-cell lung cancer.

  1992cited by this paper
• Angiogenesis, assessed by platelet/endothelial cell adhesion molecule antibodies, as indicator of node metastases and survival in breast cancer.

  1992cited by this paper
• Molecular and biological properties of the vascular endothelial growth factor family of proteins.

  1992cited by this paper
• Tumor angiogenesis and metastasis--correlation in invasive breast carcinoma.

  1991cited by this paper
• Regulators of angiogenesis.

  1991cited by this paper
• The fibroblast growth factor family.

  1991cited by this paper
• The fibroblast growth factor family.

  1990cited by this paper

• Epidermal growth factor receptor tyrosine kinase inhibitor for the treatment of non-small cell lung cancer in the past 30 years (1997-2026).

  2026cites this paper
• Addition of bevacizumab to gefitinib plus chemotherapy as first-line therapy in EGFR L858R mutate advanced non-small cell lung cancer patients

  2025cites this paper
• EGFR: New Insights on Its Activation and Mutation in Tumor and Tumor Immunotherapy

  2025cites this paper
• Efficacy and prognostic analysis of chemo-immunotherapy after TKI resistance in EGFR-mutant non-small cell lung cancer with TP53 or KRAS co-mutations

  2025cites this paper
• Pharmacogenomics and Personalized Medicine

  2024cites this paper
• The Nail in the Coffin?: Examining the KEYNOTE-789 Clinical Trial’s Impact

  2024cites this paper
• A strategic review of STAT3 signaling inhibition by phytochemicals for cancer prevention and treatment: An update.

  2024cites this paper
• Outcome benefits of bevacizumab biosimilar (SIBP04) combined with carboplatin and paclitaxel in advanced non-squamous non-small-cell lung cancer patients with EGFR mutation: subgroup analysis of a prospective, randomized phase III clinical trial

  2023cites this paper
• Current treatment strategies for EGFR-mutated non-small cell lung cancer: from first line to beyond osimertinib resistance

  2023cites this paper
• A review of targeted therapy and immune checkpoint inhibitors for metastatic colorectal cancer.

  2023cites this paper
• Development of a Cu/ZnO@ZIF-8 nanocomposite as a pH-responsive drug delivery vehicle for the sustained release of doxorubicin in human lung cancer cell lines

  2023cites this paper
• The potential of phytochemicals against epidermal growth factor receptor tyrosine kinase (EGFRK): an insight from molecular dynamic simulations

  2023influential citation
• Risk factors for thromboembolism during first-line treatment of patients with unresectable advanced or recurrent colorectal cancer: a retrospective short study

  2023cites this paper
• An Overview of the Use of Anti-Angiogenic Agents in the Treatment of Thymic Epithelial Tumors

  2023cites this paper
• The Role of Targeted Therapy in the Multi-Disciplinary Approach to Colorectal Liver Metastasis

  2023cites this paper
• Effect of algal metabolites in the inhibition of angiogenic channels for breast tumour

  2023cites this paper
• Histone Methyltransferase KMT2B Promotes Metastasis and Angiogenesis of Cervical Cancer by Upregulating EGF Expression

  2023cites this paper
• A Review of Translational Research for Targeted Therapy for Metastatic Colorectal Cancer

  2023cites this paper
• EGF-Dependent Activation of ELK1 Contributes to the Induction of CLDND1 Expression Involved in Tight Junction Formation

  2022cites this paper
• Anti-angiogenesis revisited: reshaping the treatment landscape of advanced non-small cell lung cancer

  2022cites this paper
• mRNA–miRNA bipartite networks reconstruction in different tissues of bladder cancer based on gene co-expression network analysis

  2022cites this paper
• Image-guided drug delivery of nanotheranostics for targeted lung cancer therapy

  2022cites this paper
• Multifaceted Interplay between Hormones, Growth Factors and Hypoxia in the Tumor Microenvironment

  2022cites this paper
• Anti-angiogenic drugs in cancer therapeutics: a review of the latest preclinical and clinical studies of anti-angiogenic agents with anticancer potential

  2022cites this paper
• Structure-Based Virtual Screening, Molecular Docking, and Molecular Dynamics Simulation of VEGF inhibitors for the clinical treatment of Ovarian Cancer

  2022cites this paper
• Caveolin-1-ACE2 axis modulates xenobiotic metabolism-linked chemoresistance in ovarian clear cell carcinoma

  2022cites this paper
• IQ Motif-Containing GTPase-Activating Protein 2 Inhibits Breast Cancer Angiogenesis by Suppressing VEGFR2–AKT Signaling

  2021cites this paper
• Immune checkpoint inhibitors in EGFR-mutated non-small cell lung cancer: Dusk or Dawn?

  2021cites this paper
• The NRG3/ERBB4 signaling cascade as a novel therapeutic target for canine glioma.

  2021cites this paper
• Inhibitory effects of icotinib combined with antiangiogenic drugs in human non‐small cell lung cancer xenograft models are better than single target drugs

  2021cites this paper
• Immune Checkpoint Inhibitors in EGFR-Mutated NSCLC: Dusk or Dawn?

  2021cites this paper
• Prognostic Significance of EGFR Gene Mutation in Patients With EGFR Mutated Non-small Cell Lung Cancer Who Received Best Supportive Care Alone

  2021cites this paper
• The immunoexpression of epidermal growth factor receptor in cutaneous squamous cell carcinoma

  2021cites this paper
• Epidermal growth factor receptor blockers for the treatment of ovarian cancer ( Review )

  2021cites this paper
• The combination of bevacizumab/Avastin and erlotinib/Tarceva is relevant for the treatment of metastatic renal cell carcinoma: the role of a synonymous mutation of the EGFR receptor

  2020cites this paper
• Review on Epidermal Growth Factor Receptor (EGFR) Structure, Signaling Pathways, Interactions, and Recent Updates of EGFR Inhibitors.

  2020cites this paper
• Dual EGFR/VEGF pathway inhibition: a promising strategy for patients with EGFR-mutant NSCLC.

  2020cites this paper
• Gefitinib modulates stress fibers and tubular-like structure formation and attenuates angiogenesis in an in vivo chicken model of chorioallantoic membrane angiogenesis.

  2020cites this paper
• Correlation between the qualification for bevacizumab use and the survival of patients with non-small cell lung cancer harboring the epidermal growth factor receptor mutation: a retrospective analysis

  2019cites this paper
• Anti-angiogenesis Therapy in Cancer Treatment

  2019cites this paper
• FDA- and EMA-Approved Tyrosine Kinase Inhibitors in Advanced EGFR-Mutated Non-Small Cell Lung Cancer: Safety, Tolerability, Plasma Concentration Monitoring, and Management

  2019cites this paper
• Lung Cancer Receptors and Targeting Strategies

  2019cites this paper
• Pharmaceutical Advances and Proteomics Researches

  2019cites this paper
• MicroRNAs in cancer drug resistance: Basic evidence and clinical applications

  2018cites this paper
• Epidermal growth factor receptor blockers for the treatment of ovarian cancer.

  2018cites this paper
• Erlotinib plus either pazopanib or placebo in patients with previously treated advanced non–small cell lung cancer: A randomized, placebo‐controlled phase 2 trial with correlated serum proteomic signatures

  2018cites this paper
• Suppression of c-MET overcomes erlotinib resistance in tongue cancer cells

  2018cites this paper
• Therapy for Cancer: Strategy of Combining Anti-Angiogenic and Target Therapies

  2017cites this paper
• Flipped script for gefitinib: A reapproved tyrosine kinase inhibitor for first-line treatment of epidermal growth factor receptor mutation positive metastatic nonsmall cell lung cancer

  2017influential citation
• EGFR TKI as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer

  2017cites this paper
• Biological Principles and Clinical Application of EGFR Inhibitors in Cancer

  2017cites this paper
• Spinal cord regeneration by modulating bone marrow with neurotransmitters and Citicholine: Analysis at micromolecular level

  2017cites this paper
• Understanding the Biology Behind the EGFR to Improve NSCLC PatientsâTreatment

  2017cites this paper
• Systematic Kinase Inhibitor Profiling Identifies CDK9 as a Synthetic Lethal Target in NUT Midline Carcinoma

  2017cites this paper
• Targeted Therapies Against Growth Factor Signaling in Breast Cancer.

  2017cites this paper
• EGF regulation of proximal tubule cell proliferation and VEGF‐A secretion

  2017cites this paper
• Impact of Small Molecules on β-Catenin and E-Cadherin Expression in HPV16-positive and -negative Squamous Cell Carcinomas.

  2017cites this paper
• An overview of the role of platelets in angiogenesis, apoptosis and autophagy in chronic myeloid leukaemia

  2017influential citation
• Epidermal growth factor modulates prostate cancer cell invasive- ness regulating urokinase-type plasminogen activator activity EGF-receptor inhibition may prevent tumor cell dissemination

  2017cites this paper
• AVEMAR HT29 KOLON KANSERİ HÜCRELERİNDEKİ ANTİ-ANJİYOJENİK ETKİSİNİ COX-2 VE VEGF EKSPRESYONLARINI İNHİBE EDEREK GÖSTERİR

  2017cites this paper
• Anti‐metastatic functions of type 1 interferons: Foundation for the adjuvant therapy of cancer

  2017cites this paper
• Tumor-Stroma Crosstalk in Bone Tissue: The Osteoclastogenic Potential of a Breast Cancer Cell Line in a Co-Culture System and the Role of EGFR Inhibition

  2017cites this paper
• The Role of Angiogenesis in Cancer Treatment

  2017cites this paper
• Ultrasound Molecular Imaging of Angiogenesis Using Vascular Endothelial Growth Factor-Conjugated Microbubbles.

  2017cites this paper
• Co-delivery of oxygen and erlotinib by aptamer-modified liposomal complexes to reverse hypoxia-induced drug resistance in lung cancer.

  2017cites this paper
• Multiple dose Pharmakokinetik und Metabolismus von Erlotnib in Phase 1b klinischer Prüfung

  2016cites this paper
• Epidermal growth factor receptor mutation enhances expression of vascular endothelial growth factor in lung cancer

  2016influential citation
• Multi-Center Randomized Phase II Study Comparing Cediranib plus Gefitinib with Cediranib plus Placebo in Subjects with Recurrent/Progressive Glioblastoma

  2016cites this paper
• Interacciones entre las células madre pluripotentes del carcinoma embrionario y las células mioides peritubulares del testículo

  2016cites this paper
• Tumor Hypoxia Response After Targeted Therapy in EGFR-Mutant Non-Small Cell Lung Cancer

  2016cites this paper
• Polarization of macrophages in the tumor microenvironment is influenced by EGFR signaling within colon cancer cells

  2016cites this paper
• Inhibition of 5-lipoxygenase suppresses vascular endothelial growth factor-induced angiogenesis in endothelial cells.

  2016cites this paper
• Potent anti-angiogenic and cytotoxic effect of conferone on human colorectal adenocarcinoma HT-29 cells.

  2016cites this paper
• Gefitinib Synergizes with Irinotecan to Suppress Hepatocellular Carcinoma via Antagonizing Rad51-Mediated DNA-Repair

  2016cites this paper
• Targeting non-canonical autophagy overcomes erlotinib resistance in tongue cancer

  2016cites this paper
• APIP, an ERBB3-binding partner, stimulates erbB2-3 heterodimer formation to promote tumorigenesis

  2016cites this paper
• ER2, a novel human anti-EGFR monoclonal antibody inhibit tumor activity in non-small cell lung cancer models.

  2016cites this paper
• A prospective clinical trial to assess lapatinib effects on cutaneous squamous cell carcinoma and actinic keratosis

  2016cites this paper
• Rôle de l'intégrine α5β1 dans la biologie du glioblastome et dans la résistance aux thérapies anti-EGFR

  2015cites this paper
• Studies for development of novel quinazolinones: new biomarker for EGFR.

  2015cites this paper
• Efecto de la inhibición de la clusterina sobre la sensibilidad a los inhibidores de proteínas quinasas en células tumorales de mama

  2015cites this paper
• Mitogen-activated protein kinases and Hedgehog-GLI signaling in cancer: A crosstalk providing therapeutic opportunities?

  2015cites this paper
• Ex vivo Determination of an Estradiol Analogue-Induced Changes on Platelet Morphology and Angiogenic Biomarkers

  2015influential citation
• Discovery of novel VEGFR-2 inhibitors. Part II: biphenyl urea incorporated with salicylaldoxime.

  2015cites this paper
• Gefitinib: a review of its use in adults with advanced non-small cell lung cancer

  2015cites this paper
• Biomarker in Cisplatin-Based Chemotherapy for Urinary Bladder Cancer.

  2015cites this paper
• Study on Synthetic Process of Vandetanib

  2015cites this paper
• Chemical surface modification of porous silicon nanoparticles for cancer therapy

  2015cites this paper
• Curative effect analysis of different treatments for gefitinib-resistance advanced non-small cell lung cancer patients.

  2015cites this paper
• Antineoplastic impact of leishmanial sphingolipid in tumour growth with regulation of angiogenic event and inflammatory response

  2015cites this paper
• EGFR and HER2: Relevance in Renal Cell Carcinoma

  2015cites this paper
• Differential Effects of Tumor Secreted Factors on Mechanosensitivity, Capillary Branching, and Drug Responsiveness in PEG Hydrogels

  2015cites this paper
• Vasculogenesis and angiogenesis in nonseminomatous testicular germ cell tumors.

  2015cites this paper
• Theaflavin-3, 3′-digallate decreases human ovarian carcinoma OVCAR-3 cell-induced angiogenesis via Akt and Notch-1 pathways, not via MAPK pathways

  2015cites this paper
• Critical appraisal of the role of gefitinib in the management of locally advanced or metastatic non-small cell lung cancer

  2014cites this paper
• Emerging EGFR antagonists for breast cancer

  2014cites this paper
• The Rest of Interleukins

  2014cites this paper
• Activation of Akt by the Mammalian Target of Rapamycin Complex 2 Renders Colon Cancer Cells Sensitive to Apoptosis Induced by Nitric Oxide and Akt Inhibitor

  2014cites this paper
• MECHANISMS UNDERLYING DISTINCT EGFR VERSUS FGFR-3 AND -1 DEPENDENCY IN HUMAN BLADDER CANCER CELLS

  2014cites this paper
• Metabolic factors determining outcome in chemotherapy : studies with pazopanib

  2014cites this paper